Article
Geriatrics & Gerontology
David Basic, Elizabeth T. Huynh, Rinaldo Gonzales, Christopher G. Shanley
Summary: This study evaluated the impact of structured interdisciplinary bedside rounds (SIBR) on in-hospital falls among older patients with acute illness. The results showed that SIBR implementation led to a reduction in falls but did not significantly decrease fall-related injuries.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Oncology
Kiyohiko Hatake, Takaaki Chou, Toshihiko Doi, Yasuhito Terui, Harumi Kato, Takayuki Hirose, Sachiko Seo, Michael Pourdehnad, Yumi Ogaki, Hiroshi Fujimoto, Patrick R. Hagner, Kazuhito Yamamoto
Summary: Avadomide, a novel cereblon-binding agent, showed acceptable toxicity profile and clinically meaningful efficacy in Japanese patients with advanced solid tumors or NHL, with an overall response rate of 54%.
Article
Microbiology
David C. Griffith, Elizabeth E. Morgan, Michael N. Dudley, Jeffery S. Loutit
Summary: The study showed that Biapenem exposure increased slightly more than dose proportionally after multiple doses, with no evidence of accumulation. Urinary recovery ranged from 14.2% at 250 mg to 42.3% at 1,250 mg. Biapenem was well tolerated up to 1,000 mg doses every 8 hours, but higher incidences of nausea, vomiting, and rash were reported at 1,250 mg.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Respiratory System
Weimin Li, Sami Z. Daoud, Roopa Trivedi, Pradeep B. Lukka, Eulalia Jimenez, Eduard Molins, Catherine Stewart, Pranob Bharali, Esther Garcia-Gil
Summary: This study aimed to investigate the pharmacokinetics and safety profile of Aclidinium in healthy Chinese participants. The results showed that single and multiple doses of Aclidinium were well tolerated in the Chinese population, with pharmacokinetic characteristics similar to Caucasian populations.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(2023)
Article
Microbiology
Ryan T. Jarrett, Yuri van der Heijden, Matthew S. Shotwell, Violet Chihota, Mark A. Marzinke, Richard E. Chaisson, Kelly E. Dooley, Gavin J. Churchyard
Summary: This study investigated plasma isoniazid levels in 30 patients receiving 3HP and dolutegravir for LTBI and HIV treatment. The results showed that the isoniazid exposures were consistent with or greater than previously reported levels in individuals receiving 3HP and dolutegravir, and substantially higher than those in patients receiving 3HP or isoniazid without rifapentine or dolutegravir. These findings have important implications for clinical management and potential drug-drug interactions mediated by cellular transport.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
David Huang, Despina Dobbins, Parviz Ghahramani, Ian Friedland, Jonathan Steckbeck
Summary: This first-in-human study evaluated the safety and pharmacokinetics of PLG0206, a novel engineered cationic antimicrobial peptide, when administered intravenously as a single dose to healthy subjects. The study found that PLG0206 exhibited linear pharmacokinetics, was well tolerated, and had a low incidence of treatment-related adverse events.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Oncology
Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, Ko Sugibayashi, Kosho Murayama, Noboru Yamamoto
Summary: This study evaluated the safety and antitumor activity of oleclumab in adult Japanese patients with advanced solid malignancies. The results showed that oleclumab was well tolerated and no unexpected safety concerns were raised.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Deborah M. Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Casey B. Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A. Rogers, Seema Bhat, Samantha M. Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach
Summary: The combination of selinexor and ibrutinib has demonstrated tolerability and durable responses in patients with relapsed/refractory CLL/NHL. Notable responses were seen in patients with CLL with minimal prior therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Clinical Neurology
Rosa Maria Antonijoan, Juan Manuel Ferrero-Cafiero, Jimena Coimbra, Montse Puntes, Joan Martinez-Colomer, Maria Isabel Arevalo, Cristina Mascaro, Cesar Molinero, Carlos Buesa, Tamara Maes
Summary: Vafidemstat showed good safety profile, pharmacokinetics and pharmacodynamics characteristics, and exhibited CNS penetration in this phase I trial, supporting further development in phase II trials for patients with CNS diseases.
Article
Microbiology
Paul Bruinenberg, Jerry Nedelman, Tian J. Yang, Fran Pappas, Dan Everitt
Summary: The study aimed to evaluate the safety and tolerability of sutezolid tablets in healthy adult subjects and determine its pharmacokinetics. The results showed that sutezolid was well tolerated in fasting healthy adults when administered in doses ranging from 300mg to 1800mg. The maximum concentration of sutezolid, PNU-101603, and PNU-101244 increased in a less-than-proportional manner with an increase in sutezolid dose, while total exposure increased proportionally with dose.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Biotechnology & Applied Microbiology
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Halimu N. Haliduola, Elin Edwald, Fausto Berti
Summary: This study assessed the pharmacokinetic similarity of AVT02 administered via prefilled syringe (PFS) or autoinjector (AI). The results demonstrated bioequivalence between the two administration methods, with similar safety and immunogenicity profiles.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Dermatology
Masataka Suehiro, Tomofumi Numata, Emi Murakami, Masakazu Takahashi, Ryo Saito, Satoshi Morioke, Akiko Kamegashira, Shunsuke Takahagi, Michihiro Hide, Akio Tanaka
Summary: The topical Janus kinase inhibitor, delgocitinib (DEL) ointment, has been shown to be effective in treating atopic dermatitis (AD). It is as effective as topical corticosteroids in maintaining remission, especially for patients with dry skin.
DERMATOLOGIC THERAPY
(2022)
Article
Oncology
Monica K. Malhotra, Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin, Hussein A. Tawbi, Ronald G. Stoller, James J. Lee, Chandra P. Belani, Alice P. Chen, Vincent L. Giranda, Stacie Peacock Shepherd, Leisha A. Emens, S. Percy Ivy, Edward Chu, Jan H. Beumer, Shannon Puhalla
Summary: The study aimed to determine the maximum tolerated dose and recommended phase 2 dose of veliparib in combination with weekly carboplatin and paclitaxel for triple negative breast cancer. The results showed that this triplet combination had promising clinical activity and was safe and feasible.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Pharmacology & Pharmacy
Xiaoyue Du, Hongxin Cai, Nan Jin, Zhiguo Wu, Lele Wang, Zeyu Wang, Baogang Xie
Summary: The study compares the pharmacokinetics and steady-state serum concentrations of lenvatinib in adult and juvenile rats. An UPLC-MS method was developed to measure lenvatinib in serum and liver. The results show that juvenile rats have lower steady-state levels of lenvatinib in the liver, potentially due to differences in CYP3A2 mRNA expression. This suggests that the dosage of lenvatinib may need to be increased for pediatric patients to achieve the desired clinical outcome.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
Luis Vitetta, Belinda Butcher, Jeremy D. Henson, David Rutolo, Sean Hall
Summary: The study investigated the safety, tolerability, and pharmacokinetics of a nanoparticle CBD formulation administered via the oro-buccal route. Results showed that the formulation achieved plasma concentrations comparable to other commercial products. No adverse effects were reported, indicating the safety and efficacy of the CBD-dominant anti-inflammatory cannabis medicine.
INFLAMMOPHARMACOLOGY
(2021)
